Teladoc Health (NYSE:TDOC) disclosed a compact insider transaction this week after Chief Accounting Officer Joseph Ronald Catapano moved to sell a portion of his holdings.
According to a Form 4 filing with the Securities and Exchange Commission, Catapano sold 675 shares of Teladoc common stock on April 2, 2026, at $5.114 per share, for proceeds of roughly $3,451. The filing also shows that on April 1 he exercised options to acquire 2,083 shares of common stock.
Following the April 2 sale, Catapano is reported to directly own 10,249 shares of Teladoc Health. The Form 4 is the public record of the transactions and provides the detailed securities activity by the company insider.
Market context
The insider sale comes as Teladoc shares are trading at about $5.27. The stock is down 25% year-to-date and has fallen 42% over the past six months. Separately, InvestingPro analysis cited in the public notice indicates a Fair Value of $8.01 for the stock, and notes that a comprehensive Pro Research Report is available for TDOC along with coverage on more than 1,400 other U.S. equities.
Recent corporate and analyst developments
- Deutsche Bank upgraded Teladoc’s rating to Buy from Hold, pointing to valuation as a key consideration.
- BofA Securities raised its rating to Buy from Neutral, citing an improved margin outlook for Teladoc’s BetterHelp business, and increased its price target to $8.25 from $7.00 following the announcement that Universal Health Services agreed to acquire Talkspace.
- Activist investor Pineal Capital Management has publicly pushed Teladoc to institute a $200 million share buyback program and undertake a strategic review, expressing dissatisfaction with the company’s capital allocation decisions.
- Teladoc added Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors; Salka will serve on the audit and compensation committees.
What the filings and recent activity show
The SEC Form 4 documents the exact share counts and prices tied to Catapano’s option exercise and subsequent sale. The sequence - exercising options on April 1 followed by a sale on April 2 - is reflected in the disclosure. The sale is modest in dollar terms relative to the company’s market capitalization, while the company’s stock price has experienced notable declines over recent periods.
Alongside the insider transaction, the company’s public profile has been active: two sell-side analysts upgraded the stock, an activist has urged a significant buyback, and a new director with health-care executive experience has been appointed to the board. These items together illustrate a mix of governance, strategic and market-valuation dynamics currently surrounding Teladoc.
Additional services noted in disclosures
The published material referenced InvestingPro’s Fair Value assessment and the availability of a Pro Research Report for TDOC and more than 1,400 other U.S. equities. It also described ProPicks AI as a tool that evaluates companies using more than 100 financial metrics and that it highlights past winners including Super Micro Computer (+185%) and AppLovin (+157%).
Investors reviewing the Form 4 and the surrounding company developments will find a compact insider sale set against a backdrop of analyst upgrades, activist pressure and a board appointment that together frame current strategic and market considerations for Teladoc.